Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8171 results

  1. Kidney Cancer Quality Standard

    In development Reference number: GID-QS10186 Expected publication date:  19 March 2026

    Quality standard
    In development

  2. Statement of intent on NICE's approach to ongoing evaluations ahead of proposed changes to NICE's standard cost-effectiveness thresholds: nice general consultation

    We are listening to your views on this NICE general. Comments close 30 January 2026.

    NICE guideline
    In consultation

  3. Levodopa inhaled for patients with Parkinson's disease who experience 'off' episodes (motor response fluctuations) [TSID8778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development Reference number: GID-TA11232 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  5. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

    In development Reference number: GID-TA11823 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development

  8. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

    Interventional procedures guidance
    In development

  9. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation

  10. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation

  11. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 9 February 2026.

    Technology appraisal guidance
    In consultation

  12. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 12 February 2026.

    Technology appraisal guidance
    In consultation

  13. Domestic Abuse: draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 27 January 2026.

    NICE guideline
    In consultation

  14. Tirzepatide for managing overweight and obesity in people 12 to 17 years [TSID12322]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Rare diseases

    In development Reference number: GID-QS10197 Expected publication date:  27 February 2026

    Quality standard
    In development